What is the role of targeted therapy in relapsed/refractory ALK+ anaplastic large cell lymphoma?

I recently had an ALCL patient with small cell pathology which, as you know, is a poor prognostic pathology. I asked the same question, and the response from the COG expert, based on the unpublished data from ANHL12P1, was not to add targeted therapy up front but to base the decision on response. I ...